Zoetis (NYSE:ZTS)

Zoetis markets a range of products for pets and farm animals, including vaccines, drugs, and pesticides.
The company was originally a subsidiary of Pfizer (NYSE:PFE), but Zoetis split from its former parent company and made its debut on the stock market in early 2013. Since then, Zoetis has easily trounced average market returns.

The stock could keep climbing because of the worldwide population growth:, the increased demand for animal protein, will also be a tailwind for the company's livestock business.
Zoetis has consistently developed new products to address the market, and thanks to the growth of the middle class (and people spending an increasing amount of money on their pets), its companion-animal business could continue to be a major tailwind.
Earlier this year, the Food and Drug Administration approved Zoetis' medicin Simparica, a chewable tablet for dogs that the company says offers protection from heartworm disease, ticks and fleas, roundworms, and hookworms.
The approval of Simparica followed that of ProHeart 12 about six months earlier. The once-yearly injection helps prevent heartworm disease in dogs that are less than a year old. ProHeart 12 was the first once-yearly injection approved for the prevention of heartworm disease in dogs, once again showing Zoetis' commitment to continuous innovation in this field.